Category: Therapeutics
-
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18
•
Article content NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. announced… (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will report its fourth-quarter and full-year 2024 financial results on Tuesday, February 18, 2025,…
-
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
•
Sangamo Therapeutics shares decline as Pfizer terminates hemophilia gene therapy agreement on monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of severe-to-moderate hemophilia A that it co-developed and licensed. Pfizer (NYSE: PFE). Pfizer has…
-
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
•
On November 21, shares rose CRISPR therapeutics (NASDAQ: CRSB) Prices fell by 47% from their peak in March. This may be a bit surprising to people who follow this developer of gene therapies. After all, it’s been less than a year since U.S. and European Union regulators approved its first…
-
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lun
•
The first scientific presentation of previously announced data from Cohort 1 of an ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg twice daily) in IPF, confirms positive trends in seven of the eight biomarkers evaluated, suggesting to a potential therapeutic effect Enrollment in the second cohort evaluating high-dose…
-
Eliem therapeutics executive sells over $9,000 in company stock By Investing.com
•
According to a new filing with the U.S. Securities and Exchange Commission, Emily Pimblett, chief accounting officer of Eliem Therapeutics, Inc. (NASDAQ:ELYM), recently sold a portion of her company’s stock. The transactions, which took place on September 20, 2024, involved the sale of 1,182 shares at $8.18 each and 9…
-
Eliem therapeutics executive sells over $9,000 in company stock By Investing.com
•
According to a new filing with the U.S. Securities and Exchange Commission, Emily Pimblett, chief accounting officer of Eliem Therapeutics, Inc. (NASDAQ:ELYM), recently sold a portion of her company’s stock. The transactions, which took place on September 20, 2024, involved the sale of 1,182 shares at $8.18 each and 9…
-
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress By Investing.com
•
BOSTON–(BUSINESS WIRE)–Asteria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immune diseases, today announced that it will present preliminary data for nafinibart alfa-star at the upcoming European Academy of Dermatology & Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024. Dr.…
-
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock By Investing.com
•
WALTHAM, Mass.–(BUSINESS WIRE)– Viridian Therapeutics (Nasdaq: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for the treatment of serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock and, in lieu of common stock for certain investors,…
-
Biora Therapeutics reports progress on BT-600 and BioJet platforms By Investing.com
•
Biora Therapeutics has reported significant advancements in its BT-600 program and BioJet platform during its recent earnings call. The company announced successful Phase I clinical trial results for its BT-600 program, utilizing the NaviCap platform for targeted drug delivery to the colon. This approach demonstrated a lower systemic drug level…
-
Scotiabank sees ‘deep value’ in Sage Therapeutics stock despite study setback By Investing.com
•
On Wednesday, Scotiabank revised its outlook on Sage Therapeutics (NASDAQ:SAGE), lowering its price target to $17 from $19 previously while maintaining a sector outperform rating on the stock. The decision comes after the company’s recent stock price decline due to the unsuccessful outcome of the KINETIC-2 study, which tested SAGE-324…
-
Kintara Therapeutics restructures share designations By Investing.com
•
In a recent move, Kentara Therapeutics, a San Diego, California-based pharmaceutical company, has officially withdrawn its designation of two types of preferred stock. The company, listed on the Nasdaq Capital Market under the symbol KTRA, filed the necessary documents with the Nevada Secretary of State on Friday, July 12, 2024.…
-
Eliem Therapeutics EVP sells $338,000 in stock By Investing.com
•
Valerie Morissette, Executive Vice President of Research and Development and Chief Scientific Officer of Eliem Therapeutics, Inc. (NASDAQ:ELYM), sold a significant number of shares of the company. On July 3, 2024, Morissette disposed of 50,000 shares of common stock at an average price of $6.76, resulting in a total net…
-
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
•
New York, May 16, 2024 /PRNewswire/ — Selous Therapeutics (NASDAQ:), Inc. (Nasdaq: SEEL) (“Seelos” or the “Company”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (“CNS”) disorders and rare diseases, announced today that it has entered into a securities purchase agreement agreement with certain investors. Institutional…
-
Amicus Therapeutics CEO sells $75,523 in stock, buys options By Investing.com
•
Amicus (NASDAQ:) Therapeutics, Inc. (NASDAQ:FOLD) President and CEO Bradley L. Campbell recently engaged in transactions involving the company’s common stock, according to a new filing with the Securities and Exchange Commission. On May 1, 2024, Campbell sold 7,500 shares of his stock Amicus Treatments With a weighted average price of…